Top Story

CTL019 therapy induced sustained remission in relapsed, refractory ALL

October 30, 2014

PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at the University of Pennsylvania, discusses study results that showed chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and refractory acute lymphoblastic leukemia.

The patients who participated in these trials had relapsed as many as four times, and 60% had their cancers return following bone marrow or stem cell transplants.

figure In the Journals

Double-unit cord-blood transplant failed to extend survival in blood cancers

October 29, 2014
Children and adolescents with hematologic malignancies who underwent double-unit cord-blood transplantation experienced similar survival rates as those who underwent…
In the Journals

Gemcitabine regimen effective in relapsed, refractory aggressive lymphomas

October 28, 2014
Patients with relapsed or refractory aggressive lymphomas treated with gemcitabine, dexamethasone and cisplatin prior to autologous stem cell transplantation achieved…
In the Journals

Aprepitant regimen reduced CINV in post-transplant myeloma

October 21, 2014
The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent high-dose…
CME
figure

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Video
figure

CTL019 therapy induced sustained remission in relapsed, refractory ALL

October 30, 2014
PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

figure Video

CTL019 therapy induced sustained remission in relapsed, refractory ALL

October 30, 2014
PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at the University of Pennsylvania…
figure In the Journals

Double-unit cord-blood transplant failed to extend survival in blood cancers

October 29, 2014
Children and adolescents with hematologic malignancies who underwent double-unit cord-blood transplantation experienced similar survival rates as…
In the Journals

Gemcitabine regimen effective in relapsed, refractory aggressive lymphomas

October 28, 2014
Patients with relapsed or refractory aggressive lymphomas treated with gemcitabine, dexamethasone and cisplatin prior to autologous stem cell…
In the Journals

Aprepitant regimen reduced CINV in post-transplant myeloma

October 21, 2014
The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent…
In the Journals

Panobinostat regimen extended PFS in multiple myeloma

October 20, 2014
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as…
figure In the Journals

CTL019 therapy conferred 90% remission rate in relapsed, refractory ALL

October 15, 2014
Chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and…
figure FDA News

FDA grants priority review to blinatumomab for ALL

October 10, 2014
The FDA granted priority review status to blinatumomab, an investigational agent intended for the treatment of adults with Philadelphia…
FDA News Perspective

FDA approves Velcade regimen for treatment-naive mantle cell lymphoma

October 9, 2014
The FDA today approved the use of bortezomib as part of a combination regimen for patients with previously untreated mantle cell lymphoma, the…
In the Journals

White blood cell recovery predicted OS, PFS after HCT

HemOnc Today, October 25, 2014
A scoring system based on the pattern of peripheral white blood cell recovery within the first 3 months after allogeneic hematopoietic cell…
More Headlines »